About this trial
Diabetes mellitus (DM) is an epidemic disease, with approximately 463 million persons diagnosed with it. Of those, 90% are patients with type 2 DM (T2DM). Some estimates indicate that 700 million cases of DM will be reported in 2045. T2DM develops due to insulin resistance, leading to reduced insulin secretion. DM has a number of associated complications, such as nephropathy, neuropathy, and cardiovascular disease.
Eligibility criteria
Qualifiers
Patients diagnosed to have Uncontrolled type 2 diabetes mellitus (HbA1C more than 7%)
Disqualifiers
Patients diagnosed to have type 1 diabetes.
Patients are diagnosed to have secondary diabetes.
Anemia (Female Hb less than 12, Male Hb less than 13) either due to hemolysis, or in response to ineffective red cell production, which can be caused by deficiencies in iron, vitamin B12 or folate.
After blood transfusions
Trial design
Treatments tested in this trial
- Glycated hemoglobin (HbA1C)
- RDW
- Lipid profile